# Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216

> **NCT00161941** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 321 (—)

## Conditions studied

- Meningococcal Meninigitis, Serogroup C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00161941
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2003-12
- **Target enrollment:** 321 (—)
- **Last updated:** 2015-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00161941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00161941, "Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00161941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*